Bayer and Samsung Take Action Against Sleep Disturbances Associated with Menopause

BayerBayer AG today announced a strategic collaboration with Samsung Electronics America, Inc. to address data gaps on sleep disturbances associated with menopause (SDM). The companies will co-develop an observational study to further improve the understanding of the burden and impact of SDM using data provided by women through Samsung consumer devices.

Up to 60% of women experience sleep disturbances during menopausal transition, including difficulty falling asleep or staying asleep.(1) SDM can negatively impact women’s health and quality of life, limiting daily activities, including performance at work. Despite this impact on women’s health, current treatments do not specifically address sleep disturbances associated with menopause.

"By joining forces with Samsung and women using their devices, we strive to expand treatment options to support women at all stages of life," said Juergen Eckhardt, M.D., Head of Business Development & Licensing at Bayer's Pharmaceuticals Division. "With one of the world's largest pools of biomarker data collected with wearable devices, Samsung is a perfect partner to further enhance the knowledge base in women's health with real-world evidence."

Together with vasomotor symptoms (also known as VMS or hot flashes) and mood symptoms, sleep disturbances belong to the most frequent and disruptive symptoms associated with menopause. Bayer recently announced positive detailed results from the pivotal OASIS 1 and 2 Phase III studies of its investigational compound elinzanetant which achieved a statistically significant reduction in frequency and severity of VMS over 12 weeks compared to placebo.

The collaboration announced today will leverage Samsung's strong position in consumer wearable technology and leading expertise in sensors and devices to capture relevant digital endpoints.

"We are pleased to be partnering with Bayer to explore the connection between sleep and women's health," said Sumanth Munipalli, Head of Partnerships & Business Development, Digital Health, Samsung Electronics America. "Samsung is building powerful consumer technology to gain meaningful insights into sleeping better. As a foundation of health, good sleep is critical to our overall health and wellbeing across one's health span."

Samsung Health's end-to-end health and wellness platform, which includes its innovative health app and wearables, enables the collection of various biometric data, including temperature, sleep architecture and menstrual cycle.

Financial details were not disclosed.

About Menopause

By 2030, the global population of women experiencing menopause is projected to increase to 1.2 billion, with 47 million women entering this phase each year. Menopause is a transitional phase in women's lives, related to the progressive decline of ovarian function. It usually occurs in women during their 40s or early 50s. It can also be the result of surgical or medical treatment such as breast cancer treatment. The hormonal decline can lead to various symptoms which can substantially affect a woman's health, quality of life, healthcare utilization and work productivity. The most frequently reported and disruptive symptoms during the menopausal transition are VMS, sleep disturbances and mood changes. Addressing these symptoms is key to maintaining functional ability and quality of life in menopause which is highly relevant from both a healthcare and socio-economic perspective.

About Women's Healthcare at Bayer

As a global leader in women's healthcare Bayer has a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide and to broadening treatment choices such as in menopause. Additionally, Bayer intends to provide 100 million women per year in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs for capacity building and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

1. Nappi, RE; Kroll, R; Siddiqui, E, et al. (2021). Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause; 28 (8): 875-882.

Most Popular Now

When it comes to Emergency Care, ChatGPT…

If ChatGPT were cut loose in the Emergency Department, it might suggest unneeded x-rays and antibiotics for some patients and admit others who didn't require hospital treatment, a new study...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI Drives Development of Cancer Fighting…

University of Houston researchers and their students are developing a new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases. CellChorus...

Revolutionizing Cardiovascular Risk Asse…

A recent position paper in the Asia-Pacific Journal of Ophthalmology explores the transformative potential of artificial intelligence (AI) in ophthalmology. Led by Lama Al-Aswad, Professor of Ophthalmology and Irene Heinz...

HWL 2024 Brings Together a Record Number…

1 - 2 October 2024, Luxembourg. The second edition of Healthcare Week Luxembourg on 1 and 2 October 2024, organised by the Federation of Luxembourg Hospitals (FHL), in partnership with the...

Why the NHS Needs a Transparency Revolut…

Opinion Article by Dr Mark Ratnarajah, NHS paediatrician and UK Managing Director for C2-Ai. Wes Streeting wanted 'no stone left unturned' when he asked Lord Darzi to examine the current state...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Great Start for Ideas and Innovations: D…

8 - 10 April 2025, Berlin, Germany. From 15 October to 15 November 2024, the DMEA invites experts from business, science, politics and practice to actively participate in shaping the congress...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...